Quinupristin/dalfopristin

Drug Profile

Quinupristin/dalfopristin

Alternative Names: RP 57669/RP54476; RP 59500

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antibacterials; Streptogramins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Enterococcal infections; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections

Most Recent Events

  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top